1220886-29-2Relevant articles and documents
Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria
Skepper, Colin K.,Armstrong, Duncan,Balibar, Carl J.,Bauer, Daniel,Bellamacina, Cornelia,Benton, Bret M.,Bussiere, Dirksen,De Pascale, Gianfranco,De Vicente, Javier,Dean, Charles R.,Dhumale, Bhavesh,Fisher, L. Mark,Fuller, John,Fulsunder, Mangesh,Holder, Lauren M.,Hu, Cheng,Kantariya, Bhavin,Lapointe, Guillaume,Leeds, Jennifer A.,Li, Xiaolin,Lu, Peichao,Lvov, Anatoli,Ma, Sylvia,Madhavan, Shravanthi,Malekar, Swapnil,McKenney, David,Mergo, Wosenu,Metzger, Louis,Moser, Heinz E.,Mutnick, Daniel,Noeske, Jonas,Osborne, Colin,Patel, Ashish,Patel, Darshit,Patel, Tushar,Prajapati, Krunal,Prosen, Katherine R.,Reck, Folkert,Richie, Daryl L.,Rico, Alice,Sanderson, Mark R.,Satasia, Shailesh,Sawyer, William S.,Selvarajah, Jogitha,Shah, Nirav,Shanghavi, Kartik,Shu, Wei,Thompson, Katherine V.,Traebert, Martin,Vala, Anand,Vala, Lakhan,Veselkov, Dennis A.,Vo, Jason,Wang, Michael,Widya, Marcella,Williams, Sarah L.,Xu, Yongjin,Yue, Qin,Zang, Richard,Zhou, Bo,Rivkin, Alexey
, p. 7773 - 7816 (2020)
Since their discovery over 5 decades ago, quinolone antibiotics have found enormous success as broad spectrum agents that exert their activity through dual inhibition of bacterial DNA gyrase and topoisomerase IV. Increasing rates of resistance, driven lar
QUINAZOLINONES AS PARP14 INHIBITORS
-
Paragraph 0242; 0751; 0752; 0753, (2019/07/10)
The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
Condensed derivatives of imidazole useful as pharmaceuticals
-
Paragraph 0337, (2015/09/23)
The invention relates to the compounds (I) and their acids and bases salts: wherein: the dotted line indicates a double bond; X is N or C-R1 and Y is N or C-R2, X and Y not being simultaneously N; A is selected from the group consisting of phenyl, naphthyl and (5-11) membered monocyclic or bicyclic unsaturated cycle or heterocycle possibly substituted as defined in the application, and A can also comprise either a further (4-7) membered heterocycle, said heterocycle being a monocycle, fused, saturated or unsaturated, the polycyclic system then comprising up to 14 members and up to 5 heteroatoms selected from N, O and S; B is Hydrogen or a substituent as defined in the application, or B is a (4-10) membered mono or bicyclic saturated or unsaturated heterocycle containing 1-3 heteroatoms selected from N, O and S, and possibly substituted as defined in the application; B not being Hydrogen when X is N and Y is C-R2; R1 is Hydrogen or a substituent as defined in the application; B and R1 cannot be simultaneously Hydrogen; R2 is Hydrogen or Halogen; their preparation, their use in the antibacterial prevention and therapy, alone or in association with antibacterials, antivirulence agents or drugs reinforcing the host innate immunity, and pharmaceutical compositions and associations containing them.
